Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:34:07.036Z.
Consensus retrieved: 2026-10-06T16:15:24.108Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:34:07.036Z.
Quote observation: 2026-10-06T17:27:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a4f1da35868143a3e9cc9e15baeeae426ebbcf8636af82277700bcf7ee6cbb8a
Forward PE Ratio (N/A) = Dated Quote Price ($2.03) / Consensus Forward EPS ($-0.66)
FORWARD PE RATIO
N/A
Sera Prognostics, Inc.
Market Cap
$77.53M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Sera Prognostics, Inc. (SERA) | $77.53M | N/A |
| Pulmonx Corporation (LUNG)vs › | $77.08M | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $78.31M | N/A |
| SkinHealth Systems Inc. (SKIN)vs › | $76.37M | N/A |
| Hyperfine, Inc. (HYPR)vs › | $76.37M | N/A |
| Outset Medical, Inc. (OM)vs › | $75.35M | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $79.96M | 8.60 |
| Nutriband Inc. (NTRB)vs › | $80.11M | 4.20 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $80.90M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.03, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.66 | $-0.97 – $-0.32 | 3 | n/m |
| 2027-12-31 | $-0.54 | $-0.79 – $-0.26 | 3 | n/m |
| 2028-12-31 | $-0.50 | $-0.51 – $-0.50 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
